{"DataElement":{"publicId":"5125107","version":"1","preferredName":"JAK2 Inhibitor Administered Type","preferredDefinition":"A description of the JAK2 inhibitor that was administered.","longName":"5118753v1.0:5125104v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5118753","version":"1","preferredName":"JAK2 Inhibitor Administered","preferredDefinition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades._The act of having given something (e.g., a medication or test).","longName":"5118751v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5118751","version":"1","preferredName":"JAK2 Inhibitor","preferredDefinition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","longName":"C125450","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B06D2EA-F3EF-DC2E-E050-BB89AD430759","latestVersionIndicator":"Yes","beginDate":"2016-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-05","modifiedBy":"ONEDATA","dateModified":"2016-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B06D2EA-F3FD-DC2E-E050-BB89AD430759","latestVersionIndicator":"Yes","beginDate":"2016-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-05","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5125104","version":"1","preferredName":"JAK2 Inhibitor Type","preferredDefinition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades._Something distinguishable as an identifiable class based on common qualities.","longName":"5125104v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other JAK 2 inhibitor","valueDescription":"Other JAK2 Inhibitor","ValueMeaning":{"publicId":"5125105","version":"1","preferredName":"Other JAK2 Inhibitor","longName":"5125105","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A85B-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C0D42D8-A874-AEAF-E050-BB89AD430679","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"ONEDATA","dateModified":"2016-02-18","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C0D42D8-A896-AEAF-E050-BB89AD430679","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"ONEDATA","dateModified":"2016-02-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5125103","version":"1","preferredName":"JAK2 Inhibitor Type","preferredDefinition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.:Something distinguishable as an identifiable class based on common qualities.","longName":"C125450:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JAK2 Inhibitor","conceptCode":"C125450","definition":"Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A834-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"ONEDATA","dateModified":"2016-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A845-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the JAK2 inhibitor a","type":"Preferred Question Text","description":"What was the JAK2 inhibitor administered?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A8B9-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"NYCHM","dateModified":"2017-02-01","changeDescription":",","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}